Esco Medical has selected CHLOE EQ from Fairtility as the artificial intelligence (AI) decision support tool for integration with its MIRI Time-Lapse Incubators (TLI).

With its transparent AI embryo quality assessment expertise, CHLOE EQ will enable AI output for recommending embryos that are most likely to lead to implantation in an IVF cycle.

The partnership will offer a combined solution comprising the MIRI TLI and CHLOE EQ integrated into the MIRI server.

CHLOE EQ can capture and process a vast amount of data points for each embryo, enabling the automatic input of embryo annotations logged into the electronic medical record.

It leverages this data to generate an embryo-quality score which will be coupled with biological data and insights to explain the data output of the system.

With CHLOE EQ’s automation capabilities, embryologists will get access to previously unachievable data for consistent and standardised embryo selection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The transparent AI of CHLOE EQ helps embryologists reduce manual annotation time by around 33% per cycle, leading to a 50% increase in availability at fertility clinics.

Esco Medical sales and marketing global head and director Dr Sanjay Bhojwani said: “The transparency of CHLOE EQ’s analysis maximises the impact of our time-lapse embryo image capture with AI-driven insights supported by clear biological data.

“We believe the combination of these two technologies will improve the standard of care through automation and increased transparency for both IVF professionals and patients.”